Patent
Glucagon like peptide analogs, composition, and method of use
| العنوان: | Glucagon like peptide analogs, composition, and method of use |
|---|---|
| Patent Number: | 9,487,570 |
| تاريخ النشر: | November 08, 2016 |
| Appl. No: | 13/698819 |
| Application Filed: | May 17, 2010 |
| مستخلص: | The present invention relates to novel analogs of glucagon like peptide and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes. In particular, these peptide derivatives have a peptide mimic linker and provides long duration of action for the treatment of diabetes and other insulinotropic peptide related diseases, gastrointestinal function and activities associated with glucagon levels. |
| Inventors: | Hu, Shaojing (Beijing, CN); Tan, Fenlai (Beijing, CN); Wang, Yanping (Beijing, CN); Ma, Cunbo (Beijing, CN); Hu, Yunyan (Beijing, CN); Cao, Hong (Beijing, CN); Zhao, Xiangdong (Beijing, CN); Long, Wei (Beijing, CN); Wang, Yinxiang (Beijing, CN); Ding, Lieming (Beijing, CN) |
| Assignees: | BETTA PHARMACEUTICALS CO., LTD (Hangzhou, CN) |
| Claim: | 1. A GLP-1 analog which is [Q-Linker-c8, Glue22]GLP-1-(7-37)-peptide wherein Q-linker-c8 has the structure [chemical expression included] |
| Claim: | 2. A pharmaceutical composition comprising a GLP-1 analog of claim 1 and a pharmaceutically acceptable excipient. |
| Claim: | 3. The pharmaceutical composition according to claim 2 , wherein the pharmaceutical composition is suited for parenteral administration. |
| Claim: | 4. A method for preventing or treating hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, syndrome X, dyslipidemia, cognitive disorders, atherosclerosis, myocardial infarction, coronary heart disease, stroke, inflammatory bowel syndrome, dyspepsia, or gastric ulcers in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a GLP-1 analog of claim 1 . |
| Claim: | 5. A method for preventing or delaying the progression of type 2 diabetes in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a GLP-1 analog of claim 1 . |
| Claim: | 6. A method for decreasing food intake, decreasing β-cell apoptosis, increasing β-cell function and β-cell mass, or restoring glucose sensitivity to β-cells in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a GLP-1 analog of claim 1 . |
| Patent References Cited: | 2003/0220255 November 2003 Knudsen et al. 1683408 October 2005 WO 2006068910 June 2006 WO 2009030499 March 2009 |
| Other References: | Wipf et al. “Peptide-Like Molecules (PLMs): A Journey from Peptide Bond Isosteres to Gramicidin S Mimetics and Mitochondrial Targeting Agents” Chimia (Aarau) 63:764-775. Published Nov. 1, 2009. cited by examiner Burcelin et al. “Long-Lasting Antidiabetic Effect of a Dipeptidyl Peptidase IV-Resistant Analog of Glucagon-Like Peptide-1” Metabolism 48:252-258. Published Feb. 1999. cited by examiner Peptides for Youth: The Proceedings of the 20th American Peptide Symposium. Ed. S. Del Valle et al. p. 475. Published 2009. cited by examiner |
| Assistant Examiner: | Miknis, Zachary J |
| Primary Examiner: | Alstrum Acevedo, James H |
| Attorney, Agent or Firm: | Rao, Weisun Greenberg Traurig, LLP |
| رقم الانضمام: | edspgr.09487570 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |